Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET
Company Participants
Bill Slattery - VP, IR
Pravin Dugel - Executive Chairman, President, CEO
Conference Call Participants
Tazeen Ahmad - Bank of America Merrill Lynch
Biren Amin - Piper Sandler
Tara Bancroft - TD Cowen
Colleen Kusy - Baird
Kelly Shi - Jefferies
Sean McCutcheon - Raymond James
Yi Chen - H.C. Wainwright & Co.
Operator
Good morning, and welcome to the Ocular Therapeutix second-quarter 2024 earnings conference call. [Operator Instructions]. As a reminder, this conference call is being recorded and will be available for replay on the Investor Relations section of the Ocular Therapeutix website.
I would now like to turn the call over to Ocular's Vice President of Investor Relations, Bill Slattery. Please go ahead, Mr. Slattery.
Bill Slattery
Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining our financial results for the second quarter of 2024. To make the best use of your time today, Ocular's Executive Chairman, President, and CEO, Dr. Pravin Dugel, will briefly provide a summary of recent business highlights so we can quickly get to your questions.
Joining Dr. Dugel for the Q&A portion of the call will be Donald Notman, Chief Financial Officer; Dr. Nadia Waheed, Chief Medical Officer; Dr. Sanjay Nayak, Chief Strategy Officer; and Steve Meyers, Chief Commercial Officer. We refer everyone to this morning's press release and our Form 10-Q for a comprehensive update of second-quarter financial and business results.
During today's call, we will be making certain forward-looking statements, and our actual results may differ materially. Please see the Risk Factors section of our annual report on Form 10-K and our other SEC filings for details on the risks and uncertainties relating to our business.
With that, I'd like to hand the call over to Dr. Pravin Dugel to review our recent updates. Pravin?
Pravin Dugel
Thank you, Bill, and thank you to everyone for joining us today. We know this is a very busy time of the year for everyone, so let's jump right in.
When I assumed responsibility as Ocular's Chairman of the Board, President, and CEO in mid-April, the goal was simple: transform this organization into a retina-focused company and execute, execute, execute. Ocular's number-one priority today is to bring AXPAXLI to market for wet AMD as soon as possible, given the large market size and the unmet need both in terms of the need for a more sustainable treatment option and the need to improve long-term outcomes.